Biotech founders and executives in China are having to embrace continuing uncertainty around funding as the light at the end of the tunnel still appears a way off, but partnerships and alternative financing routes are providing some relief.
Many Chinese biotech executives are preparing for the worst and say the dark days in the sector are not yet numbered.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
